Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.

A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.

More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.